Online inquiry

IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ205MR)

This product GTTS-WQ205MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Esophagitis eosinophilic research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ205MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2309MR IVTScrip™ mRNA-Anti-C5, ALXN-1210(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALXN-1210
GTTS-WQ13311MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ291MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ1864MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ8577MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ11215MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ986MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ7711MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GEXMab73
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW